Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.
Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.
“Each patient, maybe each tumor, has a different profiling and the mechanism … may be different as well,” he said.
While there have been studies showing the potential for biomarkers, there need to be prospectively designed clinical trials to validate the data, he added.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More